Sign in
Not yet recruitingNo phase

First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression

Key facts

Who runs it
hemotune AG
Where
Switzerland2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
16 people, planned
Started
1 Sept 2025
Expected to end
30 Dec 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Hemosystem REBOOT
Record updated
14 March 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Written informed consent according to national requirements
  • Hospitalized in ICU or IMC at randomization
  • Expected length of intensive care unit stay (from randomization) >48 hours
  • Suspected or confirmed bacterial sepsis
  • Septic shock diagnosis at any time during ICU/IMC stay according to Sepsis - 3 criteria definition:; an infection (suspected or confirmed); persisting hypotension requiring any dose of vasopressors (norepinephrine, vasopressin) to maintain a systemic mean blood pressure > 65 mmHg despite adequate fluid resuscitation (minimum of 30 ml/kg crystalloids); elevated lactate ≥ 2.0 mmol/L with suspected hypoperfusion
  • Persistent immunosuppression defined as mHLA-DR expression levels < 5600 Ab/cell (Cyto-Chex tubes) in at least two consecutive measurements 20-72 hours apart

Who cannot take part

  • Patients post solid-organ transplantation
  • Patient with preexisting known severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS)
  • Known active malignancy (i.e. patients under active anti-malignant treatment)
  • Known history of bleeding disorders or severe coagulopathies (e.g., Hemophilia A, Hemophilia B, Idiopathic Thrombocytopenic Purpura, Von Willebrand Disease types I, II, and III)
  • Current ongoing chronic treatment using immunosuppressive biologicals or active lymphocyte therapy (e.g. endoxan, rituximab) or corticosteroid use at a dose > 10 mg/day equivalent of prednisone. However, acute treatment using a maximum dose of hydrocortisone of 200 mg/day for sepsis is allowed
  • Contraindication to use the HemoSystem:; Sensitivity / allergy to HemoSystem components; Body weight < 50 kg; Platelets count < 20,000/µL; History of heparin-induced thrombocytopenia
  • Females who are known to be pregnant or known to be breastfeeding (b-HCG testing performed in female patients aged < 55 years),
  • Active or planned extracorporeal membrane oxygenation treatment
  • Active or planned other extracorporeal blood purification treatments with systems like CytoSorb®, ToraymyxinTM, Gambro Adsorba, etc
  • Acute severe burn injury > 20% of the body surface area
  • Moribund patient with life expectancy < 48h

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this randomized controlled trial is to restore immune function by selectively removing three mediators largely contributing to sepsis-induced immunosuppression from extracorporeal circulation.

The 2 groups in the trial

  • Treatment armTreatment being tested

    The REBOOT Hemosystem will be tested in the treatment arm for a maximum of 5 treatments, the treatment will be applied in addition to standard of care alone.

    Treatment: Hemosystem REBOOT

  • Standard of careNo study treatment, for comparison

    Best standard of care will be applied to these patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center Randomized Controlled First in Human Trial to Assess the Feasibility and Preliminary Safety Data of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill PatientS with Sepsis-induced ImmunOsuppREssion (RESTORE I)
Record updated
14 March 2025